Advances in Pharmacotherapy of Alzheimer’s Disease

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 177

Special Issue Editor

E-Mail Website
Guest Editor
University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA
Interests: Alzheimer’s disease; metals in medicine; PET imaging and diagnosis

Special Issue Information

Dear Colleagues,

After almost a century since its discovery, Alzheimer’s disease (AD) is still the most common cause of dementia, affecting over 40 million people worldwide. It is considered a major health hazard that mostly affects the population aged 65 years or older, though cases of younger populations affected by the disease have been reported (early-onset AD), with AD being the fifth leading cause of global death. There is currently no cure for it nor is there a clear understanding of the etiology of the disease. Several efforts have been made during these years to find diagnosis tools and treatments with limited clinical success. The most common treatments include immunotherapy targeting one of the hallmarks of the disease, the aggregation of amyloid beta plaques, antagonists of the N-methyl-D-aspartate (NMDA) receptors, and cholinesterase inhibitors. For this Special Issue, we encourage submissions related, but not limited, to the following topics: (1) research that highlights the recent advances related to the aforementioned treatment approaches; (2) research that presents new strategies that target different etiologies such as neuroinflammation, and what role they play in the big cascade of events that culminate in neuronal degeneration; and (3) research related to the role of metals in Alzheimer’s disease therapies.

Dr. Paulina Gonzalez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Alzheimer’s disease
  • neuroinflammation
  • neurodegeneration
  • amyloid beta
  • metals in Alzheimer’s disease

Published Papers

This special issue is now open for submission, see below for planned papers.

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: PLGA nanoparticles for co-delivery of drug and gene to the brain for the treatment of Alzheimer's Disease

Back to TopTop